On June 19, Guolonghui reported that Minsheng Health (301507.SZ) recently stated during a reception for institutional investors that the company's probiotics series are produced and sold through its wholly-owned subsidiary, Zhejiang Minsheng Health Technology Co., Ltd. In order to reduce and avoid competition within the industry, the company acquired a health technology company under the same control. Currently, the company is focusing on basic work such as product and business model adjustments. Probiotics are a market that the company is paying close attention to. The company is conducting strain screening, strain library construction, and actively applying for new patents to prepare for the launch of new probiotic products in the future.

The company has always attached importance to research and development work, investing about 5% of its annual revenue in it. Before product development is approved, the company conducts sufficient and detailed market research and demonstration.